Stock Events

Stock Events

Tenax Therapeutics 

0
69
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q1 2026
Q2 2026
Next
-0.34
-0.32
-0.31
-0.3
Expected EPS
-0.309672
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-45.53MNet Income

Analyst Ratings

15.02Average Price Target
The highest estimate is 37.94.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
43%
Hold
57%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow YBOC.STU. It's not an investment recommendation.
Amazon
15
AMZN
Tesla
13
TSLA
AMD
13
AMD
NVIDIA
12
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biopharmaceutical company that competes in the development of cardiovascular drugs, similar to Tenax Therapeutics' focus.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that has a broad portfolio including cardiovascular drugs, directly competing with Tenax Therapeutics.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is involved in the discovery, development, and manufacture of healthcare products including treatments for cardiovascular diseases, making it a competitor.
Merck
MRK
Mkt Cap366B
Merck operates in the pharmaceutical industry with a focus on cardiovascular diseases among others, competing with Tenax Therapeutics.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is a global biopharmaceutical company with a focus on discovering, developing, and delivering innovative medicines, including for cardiovascular diseases.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that develops and markets therapies in areas including cardiovascular diseases.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie is a research-based biopharmaceutical company with a range of products for complex and serious health conditions, including cardiovascular diseases.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including for cardiovascular diseases.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson is a healthcare company that develops and sells a wide range of products, including pharmaceuticals for cardiovascular health.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly is a global healthcare leader that works to discover and bring life-changing medicines to those who need them, with efforts in cardiovascular disease treatments.

About

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Show more...
CEO
Christopher T. Giordano
Employees
16
Country
United States
ISIN
US88032L2097

Listings

MU
DE
YBOC.MU
XNAS
US
TENX
MU
DE
YBO0.MU
STU
DE
YBOC.STU

0 Comments

Share your thoughts

FAQ

What is Tenax Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Tenax Therapeutics stocks are traded under the ticker YBOC.STU.
When is the next Tenax Therapeutics earnings date?▼
Tenax Therapeutics is going to release the next earnings report on November 18, 2026.
What were Tenax Therapeutics earnings last quarter?▼
YBOC.STU earnings for the last quarter are -0.3 EUR per share, whereas the estimation was -0.33 EUR resulting in a +8.2% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Tenax Therapeutics revenue for the last year?▼
Tenax Therapeutics revenue for the last year amounts to 0 EUR.
What is Tenax Therapeutics net income for the last year?▼
YBOC.STU net income for the last year is -45.53M EUR.
How many employees does Tenax Therapeutics have?▼
As of September 04, 2026, the company has 16 employees.
In which sector is Tenax Therapeutics located?▼
Tenax Therapeutics operates in the Health & Wellness sector.
When did Tenax Therapeutics complete a stock split?▼
The last stock split for Tenax Therapeutics was on January 05, 2023 with a ratio of 1:20.
Where is Tenax Therapeutics headquartered?▼
Tenax Therapeutics is headquartered in CHAPEL HILL, United States.